Back to results
US 8,298,826 B2Granted
Chimaeric vector system
AssigneeCambridge Enterprise Limited
InventorsAndrew Michael Lindsay Lever, Padraig Michael Strappe
Life of this patent
Estimating the term…
Abstract
This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient to package the second vector in the SIV capsid and a heterologous gene capable of being expressed by the vector; and culturing the host cell.
Claims2
A method of expressing a therapeutic or an antigenic protein or peptide in an individual, the method comprising:
- administering to the individual an effective amount of a chimeric virus comprising a heterologous nucleic acid sequence encoding the therapeutic or the antigenic protein or peptide, or a pharmaceutical composition thereof, wherein the chimeric virus is produced by a method comprising culturing a host cell which comprises:
- a Simian Immunodeficiency Virus (SIV) Gag-Pol nucleic acid sequence under control of an expression control sequence, wherein said SIV Gag-Pol nucleic acid sequence encodes an SIV capsid,
- a vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal and the heterologous nucleic acid sequence under control of an expression control sequence,
- SIV accessory genes necessary for viral assembly, and
- a viral envelope coding sequence under control of expression control sequences;
- wherein said culturing results in said vector being packaged in the SIV capsid to produce the chimeric virus.
3 more elements
Dependencies are inferred from the claim text.